Economic Atlas
Companies/AbCellera Biologics Inc.
Company profile

AbCellera Biologics Inc.

NASDAQ: ABCL · Healthcare · Biotechnology
Canadian filerHQ Vancouver, BCCIK 0001703057Reports USD
#382 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
54D
Revenue TTM
$79.2M
Rev growth YoY (TTM)
+242.7%
Net income (FY)
-$146.4M
Employees
562
as of 2026-08-08
Market cap
$2.1B
as of 2026-08-08

Financials — latest annual

SEC EDGAR · USD-normalized
ConceptUSDNativeFY
Revenue$75.1M$75.1M2025
Net income-$146.4M-$146.4M2025
Operating income-$217.1M-$217.1M2025
Total assets$1.4B$1.4B2025
Liabilities$390.0M$390.0M2025
Equity$966.9M$966.9M2025

Revenue trend

FY2021 – FY2025 · USD
FY21
FY21
FY21
FY22
FY23
FY24
FY25

Revenue by segment

Filed disclosures · FY2025
By product
License62%
Research Fees36%
Milestone Payments1%
By geography
CANADA85%
UNITED STATES15%
The read

What is AbCellera Biologics Inc.’s revenue?

AbCellera Biologics Inc. booked $75.1M in FY2025 revenue, growing 161% year over year — faster than most Healthcare companies we track, at a -194.9% net margin.

Peers · Healthcare
CytomX Therapeutics, Inc.63CInterpharm Holdings, Inc.——Lifecore Biomedical, Inc.66BRecursion Pharmaceuticals, Inc.54DHealwell AI Inc.60COmeros Corporation65B
Key facts
CEOCarl Hansen
SectorHealthcare
IndustryBiotechnology
HeadquartersVancouver, BC
ExchangeNASDAQ: ABCL
Employees562
IPO date2020-12-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.